This article reviews the in vitro metabolic and the in vivo pharmacokinetic drug-drug interactions with antifungal drugs, including ‰uconazole, itraconazole, micafungin, miconazole, and voriconazole. In the in vitro interaction studies, the eŠects of antifungal drugs on speciˆc activities of cytochrome P450s (CYPs), including CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, in human liver microsomes are compared to predict the possibility of drug interactions in vivo. Fluconazole, micafungin, and voriconazole have lower inhibitory eŠects on CYP3A4 activities than itraconazole and miconazole, and IC 50 and/or K i values against CYP2C9 and CYP2C19 activities are the lowest for miconazole, followed by voriconazole and ‰uconazole. In in vivo pharmacokinetic studies, it is well known that itraconazole is a potent clinically important inhibitor of the clearance of CYP3A4 substrates, and ‰uconazole and voriconazole are reported to increase the blood or plasma concentrations of not only midazolam and cyclosporine (CYP3A4 substrates) but also of phenytoin (CYP2C9 substrate) and/or omeprazole (CYP2C19/CYP3A4 substrate). On the other hand, no inhibition of CYP activities except for CYP3A4 activity by micafungin is observed in vitro, and the blood concentrations of cyclosporine and tacrolimus are not aŠected by coadministration of micafungin in vivo, suggesting that micafungin would not cause clinically signiˆcant interactions with drugs that are metabolized by CYPs via the inhibition of metabolism. Miconazole is a potent inhibitor of all CYPs investigated in vitro, although there are few detailed studies on the clinical signiˆcance of this except for CYP2C9. Therefore the diŠerential eŠects of these antifungal drugs on CYP activities must be considered in the choice of antifungal drugs in patients receiving other drugs. 
には，健康人又は患者において主 In vivo pharmacokinetic inhibition eŠect b)
Inhibition is not observed at 10 and/or 25 mM concentrations, ±: Slight inhibition is observed at 10 and/or 25 mM concentrations, ＋: IC50 or Ki value is 10-50 mM, Z : IC50 or Ki value is 1-10 mM, [ : IC50 or Ki value is 0.1-1 mM, \ : IC 50 or K i value is less than 0.1 mM. b) -: No inhibition is observed, ±: AUC, Cmax, and/or t1/2 are increased 1.25-to 1.5-fold, ＋: AUC, Cmax, and/or t1/2 are increased 1.5-to 5-fold, Z : AUC, C max , and/or t 1/2 are increased to more than 5-fold, (＋): Although no clinical studies have been conducted, the inhibiton is expected, (-): Although no clinical studies have been conducted, no inhibiton is expected. 
